An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Livmarli

Chemical Namemaralixibat
Dosage FormOral solution (oral; 9.5 mg/mL)
Drug ClassInhibitors
SystemDigestive
CompanyMirum Pharmaceuticals Inc.
Approval Year2021

Indication

  • For the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Livmarli (maralixibat) Prescribing Information2021Mirum Pharmaceuticals Inc., Foster City, CA
Document TitleYearSource
A maralixibat expanded access program for patients with cholestatic pruritus associated with Alagille Syndrome (ALGS).2021U.S. National Library of Medicine